CliffBio
biologic

Perjeta

pertuzumab

Loss of exclusivityJune 2024FDA regulatory exclusivity expiry
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand namePerjeta
Active ingredientpertuzumab
Strength420MG/14ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2012
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Perjeta patent cliff — loss of exclusivity June 2024 | CliffBio